Catrin Cox

Publications by Year

Research Areas

Pancreatic and Hepatic Oncology Research, Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes, Radiomics and Machine Learning in Medical Imaging, Esophageal and GI Pathology

Most-Cited Works

• → Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial(2020)222 cited
• → Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy(2008)53 cited
• → Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma(2021)25 cited
• → Basics of diagnosis and treatment of venous thromboembolism(2025)19 cited
• → Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial(2021)18 cited
• → Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer(2020)14 cited
• → Outcome of Weekly Carboplatin–Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum–Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review(2019)11 cited
• → Recurrent hypoglycaemia and cognitive impairment: a 14-year follow up(2016)5 cited
• → Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.(2020)3 cited
• → Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC).(2020)3 cited